<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide is a derivative of thalidomide and is FDA-approved for the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and, in combination with <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>, for the treatment of relapsed <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Pulmonary toxicity with thalidomide is a recognized potential complication; however, there have only been two case reports in the literature of lenalidomide-associated pulmonary toxicity </plain></SENT>
<SENT sid="2" pm="."><plain>In this case, we describe a patient who developed profound <z:hpo ids='HP_0002094'>dyspnea</z:hpo>, decreased exercisetolerance, and new ground-glass opacities with reticulation, consistent with a nonspecific interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo> pattern </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical suspicion for pulmonary drug toxicity was high and lenalidomide was discontinued </plain></SENT>
<SENT sid="4" pm="."><plain>Within 2 weeks of stopping lenalidomide, the patient had significant improvement in <z:hpo ids='HP_0002094'>dyspnea</z:hpo> and interstitial changes on CT were resolving </plain></SENT>
<SENT sid="5" pm="."><plain>After 8 weeks, there was complete resolution of symptoms </plain></SENT>
<SENT sid="6" pm="."><plain>Lenalidomide-induced pulmonary toxicity is significantly debilitating but, to date, it appears to be reversible with discontinuation of the medication </plain></SENT>
</text></document>